{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:54:57Z","timestamp":1771512897628,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eNeurologicalSci"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ensci.2022.100420","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:09:42Z","timestamp":1660716582000},"page":"100420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Headache: Treatment update"],"prefix":"10.1016","volume":"29","author":[{"given":"Oyindamola I.","family":"Ogunlaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ensci.2022.100420_bb0005","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"Stovner","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ensci.2022.100420_bb0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0301-0082(00)00010-1","article-title":"The pharmacology of headache","volume":"62","author":"Goadsby","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ensci.2022.100420_bb0015","series-title":"Harrison's Principles of Internal Medicine, 20e","article-title":"Migraine and other primary headache disorders","author":"Goadsby","year":"2018"},{"key":"10.1016\/j.ensci.2022.100420_bb0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1749-6632.1990.tb16912.x","article-title":"Serotonin and migraine","volume":"600","author":"Humphrey","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Suppl. 4","key":"10.1016\/j.ensci.2022.100420_bb0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/head.12601","article-title":"Triptans in the acute treatment of migraine: a systematic review and network meta-analysis","volume":"55","author":"Cameron","year":"2015","journal-title":"Headache."},{"key":"10.1016\/j.ensci.2022.100420_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT(1F) receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"24","key":"10.1016\/j.ensci.2022.100420_bb0035","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.ensci.2022.100420_bb0040","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain."},{"issue":"5","key":"10.1016\/j.ensci.2022.100420_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2732","article-title":"Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls","volume":"35","author":"Pearlman","year":"2020","journal-title":"Hum. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.ensci.2022.100420_bb0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"23","key":"10.1016\/j.ensci.2022.100420_bb0060","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ensci.2022.100420_bb0065","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the achieve II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.ensci.2022.100420_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/head.13682","article-title":"Long-term safety evaluation of Ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial","volume":"60","author":"Ailani","year":"2020","journal-title":"Headache."},{"issue":"10200","key":"10.1016\/j.ensci.2022.100420_bb0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.ensci.2022.100420_bb0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1S","key":"10.1016\/j.ensci.2022.100420_bb0085","first-page":"18","article-title":"Rimegepant 75 mg, an oral calcitonin gene-related peptide antagonist, for the acute treatment of migraine: two phase 3, double-blind, randomized, placebo-controlled trials","volume":"38","author":"Lipton","year":"2018","journal-title":"Cephalalgia."},{"issue":"9","key":"10.1016\/j.ensci.2022.100420_bb0090","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/03331024211000311","article-title":"Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: achieve I and II","volume":"41","author":"Hutchinson","year":"2021","journal-title":"Cephalalgia."},{"issue":"1","key":"10.1016\/j.ensci.2022.100420_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies","volume":"55","author":"Marmura","year":"2015","journal-title":"Headache."},{"issue":"7","key":"10.1016\/j.ensci.2022.100420_bb0100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American headache society consensus statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.ensci.2022.100420_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000441-196707000-00001","article-title":"Cardiac and pulmonary fibrosis during methysergide therapy for headache","volume":"254","author":"Graham","year":"1967","journal-title":"Am J Med Sci"},{"issue":"17","key":"10.1016\/j.ensci.2022.100420_bb0110","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.ensci.2022.100420_bb0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine \u2014 current understanding and treatment","volume":"346","author":"Goadsby","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ensci.2022.100420_bb0120","first-page":"22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J. Manag. Care Pharm."},{"issue":"22","key":"10.1016\/j.ensci.2022.100420_bb0125","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of Erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ensci.2022.100420_bb0130","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia."},{"issue":"6","key":"10.1016\/j.ensci.2022.100420_bb0135","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"issue":"19","key":"10.1016\/j.ensci.2022.100420_bb0140","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ensci.2022.100420_bb0145","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ensci.2022.100420_bb0150","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol."},{"issue":"24","key":"10.1016\/j.ensci.2022.100420_bb0155","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.ensci.2022.100420_bb0160","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia."},{"issue":"3","key":"10.1016\/j.ensci.2022.100420_bb0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia."},{"issue":"13","key":"10.1016\/j.ensci.2022.100420_bb0170","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.ensci.2022.100420_bb0175","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients - a review of pros and cons","volume":"18","author":"Deen","year":"2017","journal-title":"J. Headache Pain"},{"issue":"2","key":"10.1016\/j.ensci.2022.100420_bb0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia."},{"issue":"1","key":"10.1016\/j.ensci.2022.100420_bb0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: new drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J. Headache Pain"},{"issue":"5","key":"10.1016\/j.ensci.2022.100420_bb0190","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.ensci.2022.100420_bb0195","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention","volume":"94","author":"Kudrow","year":"2020","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.ensci.2022.100420_bb0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J. Headache Pain"},{"issue":"10161","key":"10.1016\/j.ensci.2022.100420_bb0205","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet."},{"issue":"10203","key":"10.1016\/j.ensci.2022.100420_bb0210","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.ensci.2022.100420_bb0215","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol."},{"issue":"10268","key":"10.1016\/j.ensci.2022.100420_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.ensci.2022.100420_bb0225","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.ensci.2022.100420_bb0230","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ensci.2022.100420_bb0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11916-017-0651-7","article-title":"Headache in resource-limited settings","volume":"21","author":"Woldeamanuel","year":"2017","journal-title":"Curr. Pain Headache Rep."}],"container-title":["eNeurologicalSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650222000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650222000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:18:53Z","timestamp":1762503533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405650222000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":46,"alternative-id":["S2405650222000296"],"URL":"https:\/\/doi.org\/10.1016\/j.ensci.2022.100420","relation":{},"ISSN":["2405-6502"],"issn-type":[{"value":"2405-6502","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Headache: Treatment update","name":"articletitle","label":"Article Title"},{"value":"eNeurologicalSci","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ensci.2022.100420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100420"}}